Related Experiment Video
Updated: May 30, 2026
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
Pramipexole extended release in Parkinson's disease
Eva-Maria Hametner1, Klaus Seppi, Werner Poewe
1Department of Neurology, Innsbruck Medical University, Anichstraße 35, A-6020 Innsbruck, Austria.
Expert Review of Neurotherapeutics
|August 26, 2011
Summary
Pramipexole extended release (ER) offers a new once-daily treatment for Parkinson's disease (PD). This formulation provides steady plasma levels and improved compliance compared to immediate-release pramipexole.
Area of Science:
- Pharmacology
- Neurology
- Clinical Trials
Background:
- Pramipexole is a nonergot dopamine agonist used for Parkinson's disease (PD).
- Pramipexole extended release (ER) is a novel once-daily formulation.
- Approved for early PD monotherapy and advanced PD adjunct therapy.
Purpose of the Study:
- Review pharmacological and clinical data of pramipexole ER.
- Highlight advantages over immediate-release (IR) formulation.
- Assess efficacy and tolerability in PD patients.
Main Methods:
- Double-blind, randomized, placebo-controlled trials.
- Active comparator trials in early and advanced PD.
- Evaluation of overnight switch from pramipexole IR to ER.
Main Results:
- Pramipexole ER demonstrated superiority over placebo in early and advanced PD.
- Over 80% success rate in switching patients from pramipexole IR to ER.
- Similar adverse event profile to pramipexole IR.
Conclusions:
- Pramipexole ER offers improved compliance and steady plasma levels.
- Effective and well-tolerated for Parkinson's disease management.
- Successful alternative for patients on pramipexole IR.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...